Orsobio Inc. - Page 1

Light micrograph and 3D illustration of adipose tissue.

Endocrine/metabolic

TLC-1180 supports durable weight loss and metabolic gains in combination approaches

July 1, 2025

Synthetic mitochondrial protonophores uncouple ATP production, increasing tricarboxylic acid (TCA) cycle activity and fat oxidation to meet energy demands. This approach promotes weight loss and may also enhance glycemic control and lipid metabolism.

A microscopic image of liver tissue affected by metabolic dysfunction-associated steatotic liver disease.

Gastrointestinal

Orsobio ACMSD inhibitor reverses liver injury in preclinical models

Nov. 29, 2024

The enzyme aminocarboxymuconate semialdehyde decarboxylase (ACMSD) is a regulator of de novo NAD+ synthesis and is reduced in patients with advanced liver disease.

Endocrine/metabolic

Orsobio raises funds to advance mitochondrial protonophores for obesity

Sep. 10, 2024

Orsobio Inc. has closed an oversubscribed $67 million series B financing, the proceeds of which will be used to accelerate development of its mitochondrial protonophore portfolio for the treatment of obesity and associated metabolic disorders.

Newco news

Getting its bear-ings: Orsobio raises a $60M series A

Nov. 8, 2023

By Lee Landenberger

Orsobio Inc., already in the clinic with three candidates, has completed its $60 million series A financing. The company, CEO Mani Subramanian told BioWorld, has taken its time to find the right programs, put them together and only raised capital when it saw the programs had legs. Even the series A is a measured step, as Subramanian called the financing “modest.”

3D illustration of liver and photomicrograph showing triglyceride fat accumulated in liver cells.

Endocrine/Metabolic

LXR inverse agonist TLC-2716 reduces lipogenesis in preclinical models

Nov. 23, 2022

The liver X receptor (LXR) is a nuclear hormone receptor that is one of the most important regulators of cholesterol homeostasis and plays a key role in triglyceride (TG) regulation. Researchers from Orsobio Inc. and Phenex Pharmaceuticals AG have presented preclinical data on TLC-2716, a potent, small-molecule LXR inverse agonist for the treatment of lipid disorders.

Endocrine/Metabolic

TLC-6740 demonstrates multiple metabolic benefits in vivo

Nov. 22, 2022

Scientists from Orsobio Inc. and affiliated organizations have described preclinical data for the novel liver-targeted mitochondrial protonophore TLC-6740, being developed for the treatment of metabolic disease. In vitro, mild mitochondrial uncoupling caused by TLC-6740 had pleotropic metabolic benefits in multiple cell lines. TLC-6740 increased mitochondrial potential, oxygen consumption rate and tricarboxylic acid (TCA) cycle flux, and it also inhibited de novo lipogenesis with EC50 values of 6.9 µM.